Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Immunotherapy

The FDA granted accelerated approval to nivolumab based on a notable clinical benefit in a subset of patients who progressed after receiving the standard first-line chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan.

Interim data from a recent clinical trial of nelipepimut-S plus trastuzumab showed a disease-free survival advantage compared with trastuzumab alone in patients with HER2 1+/2+ breast cancer.

“The combination of atezolizumab and cobimetinib represents the first potential immune-modifying combination for patients with microsatellite stable metastatic colorectal cancer,” said Johanna C. Bendell, MD, at the 2018 Gastrointestinal Cancers Symposium.

As the number of patients receiving immune checkpoint blockade grows, the combination of radiation and immunotherapy has become increasingly relevant, particularly in the palliative care setting, where radiation therapy is used to treat painful lesions or brain metastases.

Despite remarkable advance in the treatment of cancer through the use of immunotherapy, outcomes still vary, and, for some patients, these regimens provide only a short-term answer.
The power to fight a virtually infinite array of pathogens is one of the hallmarks of the human immune system, and random diversity is its secret weapon.
Response is a poor outcome measure of immunotherapy, according to Tanguy Seiwert, MD, who addressed this and other concerning issues in immunotherapy at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
At the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, several sessions focused on recent advances in melanoma, including new ways to boost the activity of current therapies, the development of a new class of immunotherapy, and a new form of immunotherapy—an oncolytic vaccine.
Page 2 of 2
Results 11 - 19 of 19